Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Nicotinic α4β2 Cholinergic Receptor Influences on Dorsolateral Prefrontal Cortical Neuronal Firing during a Working Memory Task.

Sun Y, Yang Y, Galvin VC, Yang S, Arnsten AF, Wang M.

J Neurosci. 2017 May 24;37(21):5366-5377. doi: 10.1523/JNEUROSCI.0364-17.2017. Epub 2017 Apr 27.

PMID:
28450546
2.

Levamisole: A Positive Allosteric Modulator for the α3β4 Nicotinic Acetylcholine Receptors Prevents Weight Gain in the CD-1 Mice on a High Fat Diet.

Lewis JA, Yakel JL, Pandya AA.

Curr Pharm Des. 2017;23(12):1869-1872. doi: 10.2174/1381612822666161201145648.

PMID:
27908269
3.

Varying Chirality Across Nicotinic Acetylcholine Receptor Subtypes: Selective Binding of Quinuclidine Triazole Compounds.

Sarasamkan J, Scheunemann M, Apaijai N, Palee S, Parichatikanond W, Arunrungvichian K, Fischer S, Chattipakorn S, Deuther-Conrad W, Schüürmann G, Brust P, Vajragupta O.

ACS Med Chem Lett. 2016 Aug 9;7(10):890-895. eCollection 2016 Oct 13.

PMID:
27774124
4.

Crystal structure of a human neuronal nAChR extracellular domain in pentameric assembly: Ligand-bound α2 homopentamer.

Kouvatsos N, Giastas P, Chroni-Tzartou D, Poulopoulou C, Tzartos SJ.

Proc Natl Acad Sci U S A. 2016 Aug 23;113(34):9635-40. doi: 10.1073/pnas.1602619113. Epub 2016 Aug 4.

5.

Postsynaptic nicotinic acetylcholine receptors facilitate excitation of developing CA1 pyramidal neurons.

Chung BY, Bignell W, Jacklin DL, Winters BD, Bailey CD.

J Neurophysiol. 2016 Nov 1;116(5):2043-2055. doi: 10.1152/jn.00370.2016. Epub 2016 Aug 3.

PMID:
27489367
6.

Associations of rare nicotinic cholinergic receptor gene variants to nicotine and alcohol dependence.

Zuo L, Tan Y, Li CR, Wang Z, Wang K, Zhang X, Lin X, Chen X, Zhong C, Wang X, Wang J, Lu L, Luo X.

Am J Med Genet B Neuropsychiatr Genet. 2016 Dec;171(8):1057-1071. doi: 10.1002/ajmg.b.32476. Epub 2016 Jul 30.

7.

nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives.

Parikh V, Kutlu MG, Gould TJ.

Schizophr Res. 2016 Mar;171(1-3):1-15. doi: 10.1016/j.schres.2016.01.020. Epub 2016 Jan 21. Review.

8.

Targeting Prefrontal Cortical Systems for Drug Development: Potential Therapies for Cognitive Disorders.

Arnsten AF, Wang M.

Annu Rev Pharmacol Toxicol. 2016;56:339-60. doi: 10.1146/annurev-pharmtox-010715-103617. Review.

9.

Cigarette Cravings, Impulsivity, and the Brain.

Potvin S, Tikàsz A, Dinh-Williams LL, Bourque J, Mendrek A.

Front Psychiatry. 2015 Sep 8;6:125. doi: 10.3389/fpsyt.2015.00125. eCollection 2015. Review.

10.

Significant association between rare IPO11-HTR1A variants and attention deficit hyperactivity disorder in Caucasians.

Zuo L, Saba L, Lin X, Tan Y, Wang K, Krystal JH, Tabakoff B, Luo X.

Am J Med Genet B Neuropsychiatr Genet. 2015 Oct;168(7):544-56. doi: 10.1002/ajmg.b.32329. Epub 2015 Jun 16.

11.

Pharmacological Characterisation of Nicotinic Acetylcholine Receptors Expressed in Human iPSC-Derived Neurons.

Chatzidaki A, Fouillet A, Li J, Dage J, Millar NS, Sher E, Ursu D.

PLoS One. 2015 Apr 23;10(4):e0125116. doi: 10.1371/journal.pone.0125116. eCollection 2015.

12.

Neurobiological impact of nicotinic acetylcholine receptor agonists: an activation likelihood estimation meta-analysis of pharmacologic neuroimaging studies.

Sutherland MT, Ray KL, Riedel MC, Yanes JA, Stein EA, Laird AR.

Biol Psychiatry. 2015 Nov 15;78(10):711-20. doi: 10.1016/j.biopsych.2014.12.021. Epub 2015 Jan 7.

13.
14.

Prefrontal Cortical Inactivations Decrease Willingness to Expend Cognitive Effort on a Rodent Cost/Benefit Decision-Making Task.

Hosking JG, Cocker PJ, Winstanley CA.

Cereb Cortex. 2016 Apr;26(4):1529-38. doi: 10.1093/cercor/bhu321. Epub 2015 Jan 16.

15.

Enantiopure Cyclopropane-Bearing Pyridyldiazabicyclo[3.3.0]octanes as Selective α4β2-nAChR Ligands.

Onajole OK, Eaton JB, Lukas RJ, Brunner D, Thiede L, Caldarone BJ, Kozikowski AP.

ACS Med Chem Lett. 2014 Sep 29;5(11):1196-201. doi: 10.1021/ml500129k. eCollection 2014 Nov 13.

16.

Striatal cholinergic interneuron regulation and circuit effects.

Lim SA, Kang UJ, McGehee DS.

Front Synaptic Neurosci. 2014 Oct 21;6:22. doi: 10.3389/fnsyn.2014.00022. eCollection 2014. Review.

17.
18.

Targeting the nicotinic cholinergic system to treat attention-deficit/hyperactivity disorder: rationale and progress to date.

Potter AS, Schaubhut G, Shipman M.

CNS Drugs. 2014 Dec;28(12):1103-13. doi: 10.1007/s40263-014-0208-9. Review.

19.

The complicated relationship between attention deficit/hyperactivity disorder and substance use disorders.

Zulauf CA, Sprich SE, Safren SA, Wilens TE.

Curr Psychiatry Rep. 2014 Mar;16(3):436. doi: 10.1007/s11920-013-0436-6. Review.

20.

Nicotinic receptors in neurodegeneration.

Posadas I, López-Hernández B, Ceña V.

Curr Neuropharmacol. 2013 May;11(3):298-314. doi: 10.2174/1570159X11311030005.

Supplemental Content

Support Center